You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 12, 2024

Investigational Drug Information for Preladenant


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug Preladenant?

Preladenant is an investigational drug.

There have been 13 clinical trials for Preladenant. The most recent clinical trial was a Phase 3 trial, which was initiated on July 14th 2010.

The most common disease conditions in clinical trials are Parkinson Disease, Movement Disorders, and Dyskinesias. The leading clinical trial sponsors are Merck Sharp & Dohme Corp., Oregon Health and Science University, and [disabled in preview].

Recent Clinical Trials for Preladenant
TitleSponsorPhase
Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062)Merck Sharp & Dohme Corp.Phase 1
A Study to Assess Pharmacokinetics of Preladenant in Participants With Chronic Hepatic Impairment (P06513)Merck Sharp & Dohme Corp.Phase 1
A Study to Assess Pharmacokinetics (PK) of Preladenant in Participants With Chronic Renal Impairment (CRI) (P06512)Merck Sharp & Dohme Corp.Phase 1

See all Preladenant clinical trials

Clinical Trial Summary for Preladenant

Top disease conditions for Preladenant
Top clinical trial sponsors for Preladenant

See all Preladenant clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.